Press releases

11
Nov 2021
22:19 E.S.T.

Cellectis Presents First Preclinical Data on UCARTMESO, an Allogeneic CAR-T Cell Product Candidate Targeting Mesothelin to Treat Solid Tumors at the Annual Meeting of the Society for Immunotherapy of Cancer

Read more
4
Nov 2021
18:51 E.S.T.

Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2021

Read more
3
Nov 2021
22:40 E.S.T.

Cellectis Announces Release of Abstracts at ASH Showcasing Updated Preliminary Clinical Data from BALLI-01 Study and First Preclinical Data from TALGlobin01

Read more
28
Oct 2021
15:08 E.S.T.

Cellectis to Hold Third Quarter Earnings Call on Friday, November 5, 2021 at 8AM EDT

Read more
19
Oct 2021
18:19 E.S.T.

Cellectis Presents Initial Preclinical Data on Two Novel Gene Therapies for Patients with RAG1 Severe Combined Immunodeficiency (SCID) and Hyper IgE syndrome at ESGCT 2021

Read more
12
Oct 2021
18:53 E.S.T.

Cellectis to Present Preclinical Data on UCARTMESO Supporting Anti-Tumor Activity at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Read more
26
Aug 2021
18:38 E.S.T.

Cellectis Announces Participation in Five Investor Conferences

Read more
5
Aug 2021
18:43 E.S.T.

Cellectis Provides Business Update and Reports Financial Results for Second Quarter and First Six Months 2021

Read more
29
Jul 2021
20:06 E.S.T.

Cellectis to Hold Second Quarter 2021 Earnings Call on Friday, August 6, 2021 at 8AM EDT

Read more
14
Jun 2021
18:11 E.S.T.

Cellectis’ Innovation Days event highlighted New Product Development, New Genome Surgery Platform .HEAL, and Manufacturing Capabilities

Read more

Press contacts

For more information on any story, or for press enquiries, get in touch with our communication team

CONTACT US